Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.60 Average PT from Brokerages

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been assigned a consensus recommendation of “Buy” from the ten research firms that are currently covering the company, MarketBeat.com reports. Ten analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $6.60.

A number of equities analysts have recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, June 20th. Piper Sandler cut their price objective on Taysha Gene Therapies from $9.00 to $7.00 and set an “overweight” rating for the company in a report on Monday, July 1st. Jefferies Financial Group reiterated a “buy” rating and issued a $8.00 price objective (up from $2.00) on shares of Taysha Gene Therapies in a report on Tuesday, May 14th. BMO Capital Markets assumed coverage on Taysha Gene Therapies in a report on Thursday, June 27th. They issued an “outperform” rating and a $5.00 price objective for the company. Finally, Chardan Capital reiterated a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, June 18th.

Taysha Gene Therapies Stock Performance

NASDAQ:TSHA opened at $2.10 on Monday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 3.38 and a current ratio of 3.38. Taysha Gene Therapies has a 52-week low of $0.66 and a 52-week high of $4.32. The firm has a market cap of $392.74 million, a price-to-earnings ratio of -4.29 and a beta of 0.41. The business’s fifty day moving average is $2.77 and its 200 day moving average is $2.51.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. Taysha Gene Therapies had a negative return on equity of 782.81% and a negative net margin of 833.60%. The company had revenue of $3.41 million for the quarter, compared to analyst estimates of $3.70 million. During the same period in the previous year, the company posted ($0.28) EPS. Research analysts predict that Taysha Gene Therapies will post -0.41 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Paul B. Manning purchased 1,333,333 shares of the business’s stock in a transaction that occurred on Thursday, June 27th. The shares were bought at an average price of $2.25 per share, for a total transaction of $2,999,999.25. Following the purchase, the insider now directly owns 1,333,333 shares of the company’s stock, valued at approximately $2,999,999.25. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.70% of the stock is currently owned by company insiders.

Institutional Trading of Taysha Gene Therapies

Several institutional investors have recently added to or reduced their stakes in the business. ADAR1 Capital Management LLC purchased a new position in shares of Taysha Gene Therapies in the 4th quarter worth $370,000. Vanguard Group Inc. boosted its stake in shares of Taysha Gene Therapies by 235.2% in the 3rd quarter. Vanguard Group Inc. now owns 5,327,864 shares of the company’s stock worth $16,836,000 after buying an additional 3,738,616 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in shares of Taysha Gene Therapies by 11.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 4,355,555 shares of the company’s stock worth $7,709,000 after buying an additional 430,555 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Taysha Gene Therapies in the 4th quarter worth $38,000. Finally, Victory Capital Management Inc. purchased a new position in shares of Taysha Gene Therapies in the 4th quarter worth $28,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.